George Ryan Patient

In January of 2017, I participated in my first endurance triathlon, the HITS 70.3 in Naples. This was swimming, biking, and running, in that order. It was a lot of fun, but after finishing, I promised myself that I would never do this again. 

Two days after the race, I was doing a run in downtown Naples where I was stopped by a couple walking on the sidewalk. The man told me that he saw me in the HITS race, and he said that I had to do the inaugural 70.3 in Lake Placid to be held in September. He mentioned that the only way possible to get a bib was by making a donation to the Multiple Myeloma Research Foundation. I said ok without knowing anything about the foundation or disease, but it sounded like a good idea.   

Training for the race was going great. In August, I had an appointment with an immunologist who was following up on frequent sinus infections and other issues. In the August visit, she told me that I needed to get some tests to screen for multiple myeloma. Two weeks later, the physicians at Moffit Cancer Center in Tampa told me that I have MGUS.  

It’s now been 6 years since the first visit to Moffit, and my condition is stable. I know much more about the disease. I started doing the events for fun. They are still fun, but now it’s more personal, and I see the benefits of the Cure Cloud and other work being done by the MMRF toward making living with the disease less difficult and hopefully finding a cure.    

Participating in endurance events and the training for them is part of my life every day. Fortunately, for me, multiple myeloma isn’t front and center, but I think about it frequently while racing, training, and living. I am hoping that my small efforts help in some way

Sorry, there are no posts from this member.
The Multiple Myeloma Research Foundation (MMRF) is the largest nonprofit in the world solely focused on accelerating a cure for each and every multiple myeloma patient. We drive the development and delivery of next-generation therapies, leverage data to identify optimal and more personalized treatment approaches, and empower myeloma patients and the broader community with information and resources to extend their lives. Central to our mission is our commitment to advancing health equity so that all myeloma patients can benefit from the scientific and clinical advances we pursue. Since our inception, the MMRF has committed over $500 million for research, opened nearly 100 clinical trials, and helped bring 15+ FDA-approved therapies to market, which have tripled the life expectancy of myeloma patients. To learn more, visit

Learn More

At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity.

Learn more About Johnson & Johnson inovative medicine Learn more About Johnson & Johnson Follow us on @JanssenUS And @JNJInnovMed